Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers

Journal of Clinical Pharmacology

Volumn 47, Issue 6, 2007, Pages 704-714

  Vanover, Kimberly E ^a,c   Robbins Weilert, Doris ^b   Wilbraham, Darren G ^b   Mant, Timothy G K ^b   Van Kammen, Daniel P ^a   Davis, Robert E ^a   Weiner, David M ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

^b IQVIA   (United States)

^c Intra Cellular Therapies Inc   (United States)

Author keywords

5 HT2A; Antipsychotic; Inverse agonist; Phase I; Serotonin

Indexed keywords

N (4 FLUOROPHENYLMETHYL) N (1 METHYLPIPERIDIN 4 YL) N' [4 (2 METHYLPROPYLOXY)PHENYLMETHYL]CARBAMIDE HYDROXYBUTANEDIOATE; SEROTONIN 2 AGONIST; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BITTER TASTE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NORMAL HUMAN; NYSTAGMUS; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; VISUAL DISORDER;

ADOLESCENT; ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; UREA;

EID: 34249040177     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007299431     Document Type: Article

References (10)

1. Vanover KE, Weiner DM, Makhay M., et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-ethylpiperidin4-yl)-N′-(4-(2- methylpropyloxy)phenylmethyl)carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-HT2A receptor inverse agonist. J Pharmacol Exp Ther. 2006 ; 317: 910-918.
2. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 ; 37: 177-193.
3. DeVane CL, Nemeroff CB Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001 ; 40: 509-522.
4. Markowitz JS, Brown CS, Moore TR Atypical Antipsychotics: Part I. Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999 ; 33: 73-85.
5. Huang M-L., Van Peer A., Woestenborghs R., et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993 ; 54: 257-268.
6. Freedman R. Schizophrenia. N Engl J Med. 2003 ; 349: 1738-1749.
7. Worrel JA, Marken PA, Beckman SE, Ruehter V. Atypical antipsychotic agents: a critical review. Am J Health-Syst Pharm. 2000 ; 57: 238-255.
8. Cubeddu LX QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther. 2003 ; 10: 452-457.
9. Haddad PM, Anderson IM Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002 ; 62: 1649-1671.
10. Harrigan EP, Miceli JJ, Anziano R., et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004 ; 24: 62-69.